SHLP2 vs Octreotide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
SHLP2
SHLP2 (Small Humanin-Like Peptide 2) is a mitochondrial-derived peptide similar to humanin. It has shown insulin-sensitizing and cytoprotective effects in research, with potential metabolic benefits.
Full details →Octreotide
Octreotide (Sandostatin) is a synthetic somatostatin analog FDA-approved for acromegaly, carcinoid tumors, and VIPomas. It inhibits growth hormone and various GI hormones.
Full details →Side-by-Side Comparison
| Aspect | SHLP2 | Octreotide |
|---|---|---|
| Mechanism | Enhances insulin sensitivity and glucose uptake. Provides cytoprotective effects similar to humanin. May act through similar but distinct receptor pathways. | Binds to somatostatin receptors (primarily SSTR2 and SSTR5) to inhibit GH, glucagon, insulin, and gastric secretions. Reduces blood flow to GI tract and inhibits tumor hormone secretion. |
| Typical Dosage | Research compound with doses in the microgram to low milligram range studied in animal models. Human dosing not established. | Varies by indication. Acromegaly: 50-100mcg three times daily initially, up to 500mcg TID. LAR (long-acting): 20-30mg IM every 4 weeks. |
| Administration | Subcutaneous or intraperitoneal injection in research settings. Various SHLP analogs (1-6) have different properties. | Subcutaneous injection for immediate-release (between meals). Intramuscular for LAR depot form. Requires monitoring of gallbladder, glucose, and thyroid. |
| Side Effects | Limited data. Animal studies suggest good tolerability. May affect glucose metabolism. | GI effects (diarrhea, nausea, abdominal pain), gallstones (up to 25% of long-term users), injection site reactions, and blood glucose changes. |
| Best For |